Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Generalized Arterial Calcification of Infancy: early-phase trial registry
1 of 3 indexed Generalized Arterial Calcification of Infancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Generalized Arterial Calcification of Infancy: 3 US clinical trials tracked, 1 recruiting.
Generalized Arterial Calcification of Infancy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Inozyme Pharma, running 3 of these trials.
Enrollment posture brief
Registry condition generalized-arterial-calcification-of-infancy
OPEN 1 | RECR 33% | LATE 1 | EARLY 2 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Generalized Arterial Calcification of Infancy lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Generalized Arterial Calcification of Infancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Generalized Arterial Calcification of Infancy is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Inozyme Pharma
NCT05734196
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Inozyme Pharma
NCT06046820
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
Inozyme Pharma
NCT04686175
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Generalized Arterial Calcification of Infancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Generalized Arterial Calcification of Infancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Generalized Arterial Calcification of Infancy page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Generalized Arterial Calcification of Infancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Inozyme Pharma sponsors the most Generalized Arterial Calcification of Infancy trials on record, review their full trial history before evaluating a specific study. See Inozyme Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Generalized Arterial Calcification of Infancy condition card totals 3 registered trials; most-linked intervention INZ-701; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.